difference between acute and chronic lymphocytic leukemia
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 1) ppsx
... the past by the Food and Drug Administration (FDA) for marketing based on trials using the FAB criteria. Acute Myeloid Leukemia Incidence The incidence of acute myeloid leukemia (AML) is ... years after exposure, and affected individuals have aberrations in chromosomes 5 and 7. Topoisomerase II inhibitor–associated leukemias occur 1–3 years after exposure, and affected individuals ... recent literature and some ongoing studies use the FAB classification, a description of this system is also provided in Table 104-1. A major difference between the WHO and FAB systems is the...
- 5
- 300
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 2) pot
... Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis ... Minimally differentiated leukemia 5% M1: Myeloblastic leukemia without maturation 20% M2: Myeloblastic leukemia with maturation 30% M3: Hypergranular promyelocytic leukemia 10% AML with 11q23 ... Myelomonocytic leukemia 20% M4Eo: Variant: Increase in abnormal marrow eosinophils M5: Monocytic leukemia 10% M6: Erythroleukemia (DiGuglielmo's disease) 4% M7: Megakaryoblastic leukemia...
- 5
- 261
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) pps
... Continuous activation of Flt3 and downstream target kinases, including signal transducer and Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) Immunophenotype and Relevance to the WHO ... for separating AML from acute lymphoblastic leukemia (ALL) and identifying some types of AML. For example, AML that is minimally differentiated (immature morphology and no lineage-specific ... Similarly, acute megakaryoblastic leukemia can often be diagnosed only by expression of the platelet-specific antigens CD41 and/ or CD61. While flow cytometry is useful, widely used, and, in some...
- 5
- 250
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) pps
... by impaired phagocytosis and migration and morphologically by abnormal lobulation and deficient granulation. Figure 104-1 Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) Clinical ... anemia. The median presenting leukocyte count is about 15,000/àL. Between 25 and 40% of patients have counts <5000/àL, and 20% have counts >100,000/àL. Fewer than 5% have no detectable leukemic ... blood. The morphology of the malignant cell varies in difference subsets. In AML the cytoplasm often contains primary (nonspecific) granules, and the nucleus shows fine, lacy chromatin with one...
- 5
- 281
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 5) docx
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 5) Morphology of AML cells. A. Uniform population of primitive myeloblasts with immature chromatin, nucleoli in some cells, and primary ... Ecchymosis and oozing from IV sites (DIC, possible acute promyelocytic leukemia) Fever and tachycardia (signs of infection) Papilledema, retinal infiltrates, cranial nerve abnormalities (CNS leukemia) ... patients, and about 25% have counts <25,000/àL. Both morphologic and functional platelet abnormalities can be observed, including large and bizarre shapes with abnormal granulation and inability...
- 6
- 255
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) pps
... achievement of CR. In addition, patients who achieve Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) Most patients are anemic and thrombocytopenic at presentation. Replacement of the appropriate ... entering CR, the length of CR, and the curability of AML. CR is defined after examination of both blood and bone marrow. The blood neutrophil count must be 1000/àL and the platelet count 100,000/àL. ... nervous system bleeding and pulmonary leukostasis contribute to poor outcome with initial therapy. In addition to pretreatment variables such as age, cytogenetics, and leukocyte count, several...
- 5
- 299
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 7) pot
... 104. Acute and Chronic Myeloid Leukemia (Part 7) Acute Myeloid Leukemia: Treatment Treatment of the newly diagnosed patient with AML is usually divided into two phases, induction and postremission ... diagnosed acute myeloid leukemia. For all forms of AML except acute promyelocytic leukemia (APL), standard therapy includes a 7-day continuous infusion of cytarabine (100–200 mg/m2 per day) and ... synthesis and thereby overcome resistance to standard-dose cytarabine. In two randomized studies, high-dose cytarabine with an anthracycline produced CR rates similar to those achieved with standard...
- 5
- 284
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) pdf
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) The hematologic toxicity of high-dose cytarabine-based induction regimens has typically been greater than that associated with 7 and 3 ... regimens. Toxicity with high-dose cytarabine includes myelosuppression, pulmonary toxicity, and significant and occasionally irreversible cerebellar toxicity. All patients treated with high-dose ... each dose, and further high-dose cytarabine should be withheld if evidence of cerebellar toxicity develops. This toxicity occurs more commonly in patients with renal impairment and in those...
- 5
- 240
- 0
báo cáo hóa học:" Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance" docx
... is a stable and inherent feature of the chronic lym-phocytic leukemia clone. Leukemia 2009, 23(6):1182-6.23. Josefsson P, Geisler CH, Leffers H, Petersen JH, Andersen MK, Jur-lander J, Buhl ... Telom-erase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients withthe same igVH mutation status and different outcome. Leukemia 2007, 21:965-972.60. ... in B cell chronic lym-phocytic leukemia. J Exp Med 2001, 194:1639-1647.64. Klein U, la-Favera R: New insights into the phenotype and cellderivation of B cell chronic lymphocytic leukemia. ...
- 14
- 640
- 0
Báo cáo hóa học: "Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patients" ppt
... pro-duced B and T cells. KRECs and TRECs are episomalDNA products generated during the lymphocyte devel-opment and differentiation process, when B- and T-cellreceptor gene rearrangements occur and ... replicated and, therefore,KRECs and TRECs are diluted when cells proliferate, and are lost when cells die. Since KRECs are randomlypresent in about 5 0% of B cells released from the bonemarrow and ... investigator and takes primary responsibility for thepaper. MM and GR recruited the patients. MC, CG, CZ and CL performed thelaboratory work for this study. LI, MM, LC and GR wrote the manuscript and participated...
- 7
- 559
- 0
Tìm thêm: xác định các mục tiêu của chương trình xác định các nguyên tắc biên soạn khảo sát chương trình đào tạo của các đơn vị đào tạo tại nhật bản khảo sát chương trình đào tạo gắn với các giáo trình cụ thể xác định thời lượng học về mặt lí thuyết và thực tế tiến hành xây dựng chương trình đào tạo dành cho đối tượng không chuyên ngữ tại việt nam khảo sát thực tế giảng dạy tiếng nhật không chuyên ngữ tại việt nam khảo sát các chương trình đào tạo theo những bộ giáo trình tiêu biểu nội dung cụ thể cho từng kĩ năng ở từng cấp độ xác định mức độ đáp ứng về văn hoá và chuyên môn trong ct phát huy những thành tựu công nghệ mới nhất được áp dụng vào công tác dạy và học ngoại ngữ mở máy động cơ lồng sóc mở máy động cơ rôto dây quấn các đặc tính của động cơ điện không đồng bộ hệ số công suất cosp fi p2 đặc tuyến mômen quay m fi p2 động cơ điện không đồng bộ một pha thông tin liên lạc và các dịch vụ phần 3 giới thiệu nguyên liệu chỉ tiêu chất lượng 9 tr 25